Tools for Practice Outils pour la pratique


#283 COVID-19 and Vitamin D: Partners in Crime, or Simply Associates?


CLINICAL QUESTION
QUESTION CLINIQUE
Does Vitamin D help prevent or treat COVID19?


BOTTOM LINE
RÉSULTAT FINAL
While observational evidence suggests an association between low vitamin D levels and COVID-19 infection, it is unclear if this is simply reflective of overall health status. There are no randomized, controlled trials (RCTs) assessing vitamin D for prevention of COVID-19 infections. The highest quality RCT of vitamin D treatment during hospitalization did not demonstrate benefit for clinical outcomes.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
3 RCTs assessed treatment in hospitalized patients with COVID-19, all received standard care in addition to oral:
  • Cholecalciferol 200,000 IU once versus placebo (240 patients, unpublished preprint).1
    • No difference in length of stay (both 7 days).
    • No difference mortality, ICU admission or ventilation.
  • Calcifediol (~21,000 IU) on day 1, (~10,000 IU) days 3 and 7, then once weekly versus usual care (76 patients, pilot study). Study length not reported.2
    • Vitamin D group showed:
      • Significant reduction ICU admission 1/50 (2%) versus 13/26 (50%).
      • Mortality 0/50 versus 2/26 (8%), not statistically different.
    • Limitations: Unbalanced randomization (more diabetes and hypertension in control), patients and physicians not blinded.
  • Cholecalciferol 60,000 IU daily x 7 days versus placebo in 40 patients with mild or no COVID-19 symptoms and Vitamin D deficient [25(OH) D <20ng/ml].3
    • Significantly more patients tested negative for COVID-19 within 21 days with vitamin D supplementation.
    • Limitations: Unclear randomization concealment and blinding, clinical outcomes not reported.
  • There are no published RCTs evaluating the use of Vitamin D for prevention of COVID-19.
  • Systematic reviews of observational studies generally demonstrate an association of low Vitamin D levels with COVID-19 infection and severity of infection, although included studies are often at high risk of bias.4-6
Context:
  • Low vitamin D is associated with poor health7 and it is unclear if low vitamin D levels are causative or simply reflect health status.
  • Additional confounders linked to COVID-19 severity and low vitamin D levels7 include higher body mass index, diabetes, older age, and Black race/ethnicity (versus non-Hispanic white).8
  • Current guidelines recommend against Vitamin D supplementation solely for prevention or treatment of COVID-19.9


Magdi Soliman April 9, 2021

Thanks


Latest Tools for Practice
Derniers outils pour la pratique

#367 Oral Calcitonin Gene-related Peptide Antagonists: A painfully long name for the acute treatment of migraines

What are the risks and benefits of ubrogepant for the acute treatment of episodic migraines?
Read Lire 0.25 credits available Crédits disponibles

#366 Looking for Closure: Managing simple excisions or wounds efficiently

What are some options for efficiency in wound closure?
Read Lire 0.25 credits available Crédits disponibles

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Christina Korownyk MD CCFP
  • Justin Weresch MD CCFP

1. Murai IH, Fernandes AL, Sales LP, et al. Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial. MedRxIv preprint. https://www.medrxiv.org/content/10.1101/2020.11.16.20232397v1Accessed January 20, 2021.

2. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. J Steroid Biochem Mol Biol. 2020; 203:105751.

3. Rastogi A, Bhansali A, Khare N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomized, placebo-controlled, study (SHADE study). Postgrad Med J. 2020 Nov 12:postgradmedj-2020-139065 (online ahead of print).

4. Pereira M, Dantas Damascena A, Galvão Azevedo LM, et al. Crit Rev Food Sci Nutr. 2020; 1- 9.

5. Liu N, Sun J, Wang X, et al. Int J Infectious Disease. 2021; 104:58-64

6. Yisak H, Ewunetei A, Kefale B, et al. Risk Management Healthcare Policy. 2021; 14:31-38.

7. Parva NR, Tadepalli S, Singh P, et al. Cureus. 2018; 10(6):e2741.

8. Wingert A, Pillay J, Gates M, et al. Risk factors for severe outcomes of COVID-19: a rapid review. MedRxiv preprint. https://www.medrxiv.org/content/10.1101/2020.08.27.20183434v1 Accessed Jan 18, 2021.

9. NICE COVID-19 rapid guideline: Vitamin D https://www.nice.org.uk/guidance/ng187/chapter/Recommendations Accessed January 18, 2021.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.